Publication | Open Access
Nociceptin inhibits cough in the guinea‐pig by activation of ORL<sub>1</sub> receptors
99
Citations
10
References
2001
Year
Pain MedicineAnesthetic MechanismMolecular PainPharmacotherapySelective OrlExperimental PharmacologyInflammationPain ManagementReceptor ActivationHealth SciencesAllergyNeuropharmacologyCapsaicin ExposurePharmacologyPain ResearchPhysiologyAnesthesiaMedicineDrug Discovery
We studied the central and peripheral antitussive effect of ORL(1) receptor activation with nociceptin/orphanin FQ in conscious guinea-pigs. In guinea-pig cough studies, nociceptin/orphanin FQ (10, 30, and 90 microg) given directly into the CNS by an intracerebroventricular (i.c.v.) route inhibited cough elicited by capsaicin exposure by approximately 23, 29 and 52%, respectively. The antitussive activity of nociceptin/orphanin FQ (90 microg, i.c.v.) was blocked by the selective ORL(1) antagonist [Phe(1)gamma(CH(2)-NH)Gly(2)]nociceptin-(1-13)-NH(2) (180 microg, i.c.v.) and J113397 (10 mg kg(-1), i.p.) but not by the opioid antagonist, naltrexone (3 mg kg(-1), i.p.). Furthermore, intravenous (i.v.) nociceptin/orphanin FQ (1.0 and 3.0 mg kg(-1)) also inhibited cough approximately by 25 and 42%, respectively. These findings indicate that selective ORL(1) agonists display the potential to inhibit cough by both a central and peripheral mechanism, and potentially represent a novel therapeutic approach for the treatment of cough.
| Year | Citations | |
|---|---|---|
Page 1
Page 1